Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03207867
Title A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

pancreatic cancer

renal cell carcinoma

triple-receptor negative breast cancer

head and neck cancer

transitional cell carcinoma

diffuse large B-cell lymphoma

colon cancer

melanoma

Therapies

PBF-509 + Spartalizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.